Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

医学 中期分析 临床终点 内科学 化疗 安慰剂 肺癌 阶段(地层学) 围手术期 肿瘤科 外科 随机化 非小细胞肺癌 临床试验 病理 古生物学 替代医学 生物 A549电池
作者
Shun Lü,Lin Wu,Wei Zhang,Peng Zhang,Wenxiang Wang,Wentao Fang,Wenqun Xing,Qixun Chen,Jiandong Mei,Lin Yang,Lijie Tan,Xiaokang Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Jinlu Shan,Nong Yang,Yuping Chen,Hui Tian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 8501-8501 被引量:15
标识
DOI:10.1200/jco.2023.41.16_suppl.8501
摘要

8501 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment, including duration of treatment, are unknown. We present the interim results of a randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of perioperative toripalimab plus chemotherapy followed by toripalimab maintenance vs chemotherapy in resectable stage III NSCLC. Methods: Patients with stage II/III resectable NSCLC, without EGFR/ALK alterations for non-squamous NSCLC, were randomized 1:1 to receive 240 mg toripalimab or placebo combined with chemotherapy Q3W for 3 cycles before surgery and one cycle after surgery, followed by toripalimab or placebo monotherapy Q3W for 13 cycles. Stratification variables for randomization included disease stage, histopathologic subtype, PD-L1 expression and surgical procedure. Primary endpoints were EFS by investigator and major pathological response (MPR) rate by a blinded independent pathologic review (BIPR) in the stage III and the ITT populations. Secondary endpoints included overall survival (OS), pathologic complete response (pCR) rate, EFS by independent review committee (IRC), and safety. A planned interim analysis was performed on the primary endpoint of EFS in the stage III subjects. Results: A total of 404 stage III NSCLC patients were randomized to toripalimab (n=202) or placebo (n=202). By the data cutoff date (November 30, 2022), the median follow-up was 18.3 months. Baseline characteristics were well balanced between the two arms. EFS was significantly improved in the toripalimab arm, HR=0.40, 95% CI (0.277-0.565), P<0.0001, and crossed the pre-specified efficacy boundary. The median EFS was not reached in the toripalimab arm and 15.1 months in the placebo arm. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups. The MPR and pCR rates per BIPR were also higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively. The OS results showed a trend favoring toripalimab. The incidence of Grade ≥3 adverse events (AEs) (63.4% vs 54.0%), fatal AEs related to toripalimab/placebo (0.5% vs 0%) and AEs leading to discontinuation of toripalimab/placebo (9.4% vs 7.4%) were comparable between the two arms. However, the incidence of immune-related AEs (42.1% vs 22.8%) was more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to perioperative chemotherapy showed statistically significant improvements in EFS for stage III NSCLC patients with a manageable safety profile. Patients will be followed for overall survival. Clinical trial information: NCT04158440 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
敏感笑槐完成签到 ,获得积分10
刚刚
Luke完成签到,获得积分10
刚刚
得鹿梦鱼完成签到,获得积分10
1秒前
嗝嗝完成签到,获得积分10
3秒前
Perry应助科研通管家采纳,获得30
3秒前
3秒前
今后应助水晶茶杯采纳,获得10
3秒前
peterlzb1234567完成签到,获得积分10
5秒前
natsu401完成签到 ,获得积分10
8秒前
mmddlj完成签到 ,获得积分10
8秒前
健康的雁凡完成签到,获得积分10
8秒前
稳重完成签到 ,获得积分10
10秒前
13秒前
haiqi完成签到,获得积分20
17秒前
白智妍发布了新的文献求助10
18秒前
王叮叮完成签到,获得积分10
19秒前
jeronimo完成签到,获得积分10
20秒前
20秒前
pcr163应助大橙子采纳,获得150
23秒前
李燕发布了新的文献求助10
25秒前
道友等等我完成签到,获得积分0
25秒前
狂野乌冬面完成签到 ,获得积分10
29秒前
xinglin完成签到 ,获得积分10
31秒前
清浅完成签到 ,获得积分10
31秒前
33秒前
34秒前
科奇完成签到,获得积分10
34秒前
可玩性完成签到 ,获得积分10
35秒前
要减肥岩完成签到,获得积分10
37秒前
Owen应助Snail采纳,获得10
39秒前
大橙子发布了新的文献求助10
39秒前
9239完成签到 ,获得积分10
40秒前
量子星尘发布了新的文献求助10
40秒前
songvv发布了新的文献求助10
40秒前
飒飒发布了新的文献求助10
41秒前
慧灰huihui完成签到,获得积分10
41秒前
Star完成签到,获得积分10
43秒前
43秒前
柔弱的不二完成签到,获得积分10
44秒前
无心的枫完成签到,获得积分10
46秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022